Evotec SE Annual General Meeting 2025 Highlights

Evotec SE recently held its Annual General Meeting (AGM) for 2025, where a significant majority of shareholders approved the proposals presented by the Company’s Management. Centered on "Pioneering Drug Discovery," CEO Dr. Christian Wojczewski provided insights into Evotec's strategic and scientific direction.

The meeting saw 46.45% of the registered share capital being represented. Key decisions included the discharge of current and former Board members from liability for the 2024 fiscal year, and approval of the Remuneration Report 2024. Amendments to allow virtual meetings and modifications to the Share Performance Plan 2022 were also endorsed.

Additionally, new Management Board members Aurélie Dalbiez and Paul Hitchin were introduced. BDO AG was confirmed as auditors for 2025. Full details and voting outcomes can be accessed on Evotec’s investor relations website.